Dr Michael Edwards
Managing & Scientific Director
Dr Michael R. Edwards is Chief Scientific Officer, Managing Director and Co-founder.
Michael Edwards received his PhD in 2001 from the University of New South Wales, Sydney, Australia investigating the molecular biology of IgE antibody responses in allergic disorders. He joined the National Heart & Lung Institute (NHLI), Imperial College London, in 2001 as a post-doctoral scientist and then progressed to Senior Lecturer of Respiratory Medicine & Infections at the NHLI. Michael’s academic work has focused on the cell and molecular biology of anti-viral immunity and inflammation in airway diseases. He has extensive experience of cellular and molecular biology of virus infections, including rhinovirus, influenza and respiratory syncytial virus, and the generation of novel anti-inflammatory and anti-viral targets for pharmaceutical intervention. He has experience in steroid biology, macrolide antibiotics and general drug discovery approaches in respiratory medicine.
At Virtus Respiratory Research, Michael brings over 18 years’ experience of working in human, animal and primary tissue culture models of rhinovirus infection to Virtus’s diverse research platform.
Michael is also responsible for the day to day running and finances of the company.
Dr Michael Edwards
Managing & Scientific Director
Dr Michael R. Edwards is Chief Scientific Officer, Managing Director and Co-founder.
Michael Edwards received his PhD in 2001 from the University of New South Wales, Sydney, Australia investigating the molecular biology of IgE antibody responses in allergic disorders. He joined the National Heart & Lung Institute (NHLI), Imperial College London, in 2001 as a post-doctoral scientist and then progressed to Senior Lecturer of Respiratory Medicine & Infections at the NHLI. Michael’s academic work has focused on the cell and molecular biology of anti-viral immunity and inflammation in airway diseases. He has extensive experience of cellular and molecular biology of virus infections, including rhinovirus, influenza and respiratory syncytial virus, and the generation of novel anti-inflammatory and anti-viral targets for pharmaceutical intervention. He has experience in steroid biology, macrolide antibiotics and general drug discovery approaches in respiratory medicine.
At Virtus Respiratory Research, Michael brings over 18 years’ experience of working in human, animal and primary tissue culture models of rhinovirus infection to Virtus’s diverse research platform.
Michael is also responsible for the day to day running and finances of the company.
